{"id":"W2898251516","doi":"10.1093/annonc/mdy284.068","title":"TALAPRO-1: An open-label, response rate phase II study of talazoparib (TALA) in men with DNA damage repair defects (DDR) and metastatic castration-resistant prostate cancer (mCRPC) who previously received taxane-based chemotherapy (CT) and progressed on ≥ 1 novel hormonal therapy (NHT)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Taxane; Prostate cancer; Clinical endpoint; Internal medicine; PARP inhibitor; Urology; Oncology; Enzalutamide; Regimen; Surgery; Clinical trial; Cancer; Breast cancer; Poly ADP ribose polymerase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001519269,0.001871802,0.001556536,0.0006649636,0.000506941,0.001277885,0.001193637,0.001678127,0.008057619],"category_scores_gemma":[0.0009705783,0.0005545304,0.001106863,0.0003400951,0.001078829,0.001231836,0.0005006519,0.003020062,0.001563899],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009475319,"about_ca_system_score_gemma":0.00162232,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008510574,"about_ca_topic_score_gemma":0.002714119,"domain_scores_codex":[0.9996501,0.0001437211,0.00001456127,0.00005689623,0.00003516673,0.00009951195],"domain_scores_gemma":[0.9992526,0.0000965123,0.0001217836,0.0000292184,0.00004333468,0.0004565355],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7556179,0.1096057,0.003577645,0.001504792,0.001015482,0.0003657207,0.0003958067,0.003317699,0.03155189,0.0007943001,0.007434083,0.08481891],"study_design_scores_gemma":[0.7026153,0.2873242,0.003960005,0.0000405565,0.0002344643,0.0002012545,0.00006193022,0.001129409,0.001814195,0.0003467333,0.00224372,0.00002830372],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9817321,0.001848958,0.0008121495,0.0008783356,0.0001553491,0.007877698,0.00236545,0.0003174015,0.004012558],"genre_scores_gemma":[0.9784654,0.001542886,0.001839717,0.001712513,0.0002308603,0.006517685,0.003092266,0.00005598634,0.006542705],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008057619,"threshold_uncertainty_score":0.02695543,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.129845030937461,"score_gpt":0.4406823153970189,"score_spread":0.3108372844595579,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}